Company
Headquarters: San Francisco, CA, United States
Employees: 1,700
CEO: Mr. Quentin S. Blackford
$4.55 Billion
USD as of July 1, 2025
Company | Market Cap (USD) |
---|---|
Intuitive | $193.76 B |
EssilorLuxottica SA | $128.90 B |
Becton, Dickinson and Company | $50.81 B |
Alcon Inc. | $44.33 B |
HOYA Corp | $40.30 B |
Company | Market Cap (USD) |
---|---|
Lilly | $699.59 B |
Johnson & Johnson | $374.29 B |
AbbVie | $336.94 B |
Novo Nordisk | $309.91 B |
UnitedHealth Group | $279.90 B |
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Last Financial Reports Date | March 31, 2025 |
Revenue TTM | $618.6 M |
EBITDA | $-58,414,000 |
Gross Profit TTM | $429.2 M |
Profit Margin | -15.90% |
Operating Margin | -19.49% |
Quarterly Revenue Growth | 20.30% |
iRhythm Technologies, Inc. has the following listings and related stock indices.
Stock: NASDAQ: IRTC wb_incandescent
Stock: FSX: I25 wb_incandescent